A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Previously Treated Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
A Study of ZN-c5 in Subjects With Breast Cancer
Sponsor: Zeno Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAS0192
U.S. Govt. ID: NCT03560531
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study involves receiving an experimental drug referred to as ZN-c5. This is the first study in humans using ZN-c5. The purpose of this research study is to test the safety of ZN-c5 at different dose levels. This study is designed to find out what effects, good and/or bad, ZN-c5 has on participants with breast cancer. Participants in both parts of the study may also be assigned to receive ZN-c5 alone, or ZN-c5 in addition to an FDA-approved medication for breast cancer called palbociclib (IBRANCE, Pfizer Inc.).
This study is closed
Investigator
Katherine Crew, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with Breast cancer? Yes No
Have you had no more than 2 prior treatments for Breast Cancer? Yes No
Are you willing to undergo additional biopsies? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE